[1] Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs. 2009 May;18(5):687-94. DOI:
10.1517/13543780902897631[2] Koh SH, et al. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther. 2021 Mar 26;13(1):66. DOI:
10.1186/s13195-021-00803-w[3] Park HH, et al. Novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiol Aging. 2014 Jun;35(6):1255-74. DOI:
10.1016/j.neurobiolaging.2013.12.015